Starpharma and Eli Lilly are working on many projects for the improvement in delivery of small molecule and protein-based pharmaceuticals, with the help of dendrimer technology by Starpharma.
Both the companies intend to expand the development dendrimer-drug conjugate program based on the results, by conducting further in vivo studies followed by clinical testing.
The nature of the product and the relating commercial terms have not been disclosed.